Printer Friendly

WARNER-LAMBERT AWARDED THIRD PATENT FOR NOVON PRODUCTS; SIGNIFICANTLY EXTENDS PATENT COVERAGE

 WARNER-LAMBERT AWARDED THIRD PATENT FOR NOVON PRODUCTS;
 SIGNIFICANTLY EXTENDS PATENT COVERAGE
 MORRIS PLAINS, N.J., March 17 /PRNewswire/ -- A patent with over 800 claims has been issued to the Warner-Lambert Company (NYSE: WLA) for its Novon Products Group. U.S. Patent No. 5,095,054, issued by the U.S. Patent and Trademark Office on starch/polymer blends, is the most far- reaching in this area and significantly extends Novon Products' patent coverage.
 The patent relates to a composition of processed starch and polymers capable of being formed into a variety of useful articles by heat and pressure. For example, food packaging and personal health care products. "This patent covers virtually all the commercially useful starch/polymer blends, and in particular, those which are completely biodegradable," said Philip M. Gross, president of Novon Products Group.
 Warner-Lambert has applied for similar patents in 39 countries, including Germany, France, Italy, Japan and the former Soviet Union. "Maintaining our leadership in processing and improving the properties of starch-based polymers is critical to Novon's long-term success," Gross continued.
 He reiterated earlier statements that Novon would "aggressively pursue companies and organizations that infringe on our distinctive technology." Simultaneous with receiving the patent, Warner-Lambert filed suit in U.S. District Court for the Southern District of New York, against Novamont North America Inc., Novamont S.p.A., and Nedermont B.V. for patent infringement.
 The Novon Products Group is fully operational, shipping product from its recently opened 100 million pound plant in Rockford, Ill. This plant is the world's largest facility dedicated to the production of biodegradable materials.
 Warner-Lambert is a worldwide company devoted to developing, manufacturing and marketing quality health care and consumer products. It employs approximately 34,000 people.
 -0- 3/17/92
 /CONTACT: Nancy Fitzsimmons of Warner-Lambert, 201-540-2145/
 (WLA) CO: Warner-Lambert Company; Novon Products Group ST: New Jersey, Illinois IN: MTC SU:


SH -- NY080 -- 8840 03/17/92 14:39 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1992
Words:318
Previous Article:MASSACHUSETTS WATER RESOURCES AUTHORITY ANNOUNCES $675 MILLION BOND ISSUE
Next Article:CULP DECLARES REGULAR QUARTERLY DIVIDEND
Topics:


Related Articles
MAJOR RIBOZYME PATENT GRANTED IN EUROPE
LIDAK PHARMACEUTICALS RECEIVES EXPANDED PATENT COVERAGE ON TOPICAL LIDAKOL(TM) CREAM
SunPharm Receives U.S. Patent Allowance For Lead Cancer Drug
Unigene Receives Notice of Allowance for Key U.S. Patent for Oral Delivery of Calcitonin for Osteoporosis Treatment
Unigene Awarded New U.S. Patent on Manufacturing Process for Osteoporosis Product
Delsys Receives Five Patents for Drug Formulation and Delivery Technology.
U.K. High Court Rules in Favor of Ranbaxy Over One Key Atorvastatin Patent, But Says Its Product Infringes Another. Ranbaxy to Appeal.
Ranbaxy Granted Permission to Appeal U.K. High Court Judgement on Patent Relating to Atorvastatin.
Patent Victory in Spanish Court Favoring Ranbaxy on Atorvastatin Unaffected.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters